Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of several malignancies. Its use, however, is associated with a number of toxic effects including adverse cutaneous reactions. Herein, we present a case of facial cystic acne in a patient receiving imatinib therapy for chronic myelocytic leukemia. This side effect resolved with cessation of therapy. To the best of our knowledge, this clinical entity has never been previously reported in the medical literature.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155218761799DOI Listing

Publication Analysis

Top Keywords

cystic acne
8
imatinib therapy
8
therapy chronic
8
chronic myelocytic
8
myelocytic leukemia
8
acne imatinib
4
leukemia imatinib
4
imatinib mesylate
4
mesylate tyrosine
4
tyrosine kinase
4

Similar Publications

Background: Acne vulgaris is a chronic, inflammatory skin disease of the pilosebaceous unit frequently cited as the most common condition diagnosed and treated by dermatologists. Among the many therapies developed for treating acne, none are effective for all patients and new treatments are always being sought. A commercial nutraceutical formulated with vitamins, minerals and a proprietary blend of botanicals has been used as a safe and effective adjunctive therapy for non-cystic acne (Clear Skin Formula; VitaMedica®).

View Article and Find Full Text PDF

A 24-years-old unmarried woman was diagnosed with polycystic ovarian syndrome (PCOS) and a complex right hemorrhagic para-ovarian cyst (POC) in January-2022. The patient started having cystic acne breakouts and weight gain in June-2021, and a stabbing pain in the right iliac region in December-2021. Thus, she visited a primary health center, South India and underwent ultrasonogram (USG) of pelvis and abdomen in a private diagnostic center in January-2022.

View Article and Find Full Text PDF
Article Synopsis
  • The case involves a man diagnosed with primary ductal adenocarcinoma of the right lacrimal gland, initially presenting as a well-defined cystic lesion.
  • The patient underwent total resection of the mass, which showed distinct histopathological features and marked tumor heterogeneity, along with successful local treatment with radiotherapy.
  • Primary ductal adenocarcinoma of the lacrimal gland is rare, and its presentation can vary, with treatment methods tailored to specific tumor characteristics.
View Article and Find Full Text PDF

Isotretinoin-Induced Skin Fragility in an Aerialist.

Cutis

July 2024

University of South Florida, Tampa. Helana Ghali is from the Morsani College of Medicine, and Dr. Albers is from the Department of Dermatology and Cutaneous Surgery.

Isotretinoin is widely used for treatment of severe cystic acne; however, its use is accompanied by mucocutaneous adverse effects. The established protocol for conducting cutaneous procedures on patients undergoing current or recent treatment with isotretinoin recommends a cessation period of at least 6 months to mitigate risks for delayed wound healing and hypertrophic scarring due to medication-induced skin fragility. We present a unique case of isotretinoin-induced skin fragility resulting in blistering and erosions on the palms of a 25-year-old competitive aerial trapeze artist.

View Article and Find Full Text PDF

Background: Acne vulgaris is a common inflammatory skin disease that occurs during puberty, affecting approximately 85% of young adults and may persist into adulthood. The pathophysiology of acne is multifactorial, involving hormonal, inflammatory, and immune mechanisms. Isotretinoin is widely used for treating severe cystic acne or recurrent acne.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!